How does respiratory syncytial virus (RSV) differ from the common cold regarding affected age groups, severity, and treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

RSV vs Common Cold: Key Clinical Differences

RSV is fundamentally more severe than the common cold, particularly affecting infants, older adults (≥75 years), and immunocompromised patients with substantially higher rates of hospitalization, ICU admission, and mortality compared to typical viral upper respiratory infections.

Affected Age Groups

High-Risk Populations for Severe RSV Disease

Infants and Young Children:

  • RSV infects nearly every child before age 2 years 1
  • Leading cause of lower respiratory tract infections in children under 1 year 2
  • 53.5% of RSV hospitalizations occur in infants <6 months 3
  • ICU admission rates remain consistently high (35-36%) across all pediatric age groups through 5 years 3

Older Adults:

  • Hospitalization rates increase dramatically with age 4:
    • Ages 18-49: 7.7-11.9 per 100,000
    • Ages 50-64: 33.5-57.5 per 100,000
    • Ages ≥65: 136.9-255.6 per 100,000
    • Ages 75-84: 210 per 100,000
    • Ages ≥85: 343 per 100,000
  • 76.3% of all adult RSV hospitalizations occur in those ≥75 years 4

Immunocompromised Patients:

  • Hospitalization rates of 1,288-1,562 per 100,000 immunosuppressed individuals 4
  • HSCT recipients: 40-60% progress from upper to lower respiratory tract infection with mortality up to 80% 4
  • HIV-infected individuals: 12-18 times higher hospitalization risk compared to HIV-negative patients 4

In contrast, the common cold affects all ages but rarely causes severe disease requiring hospitalization in otherwise healthy individuals.

Disease Severity

RSV Severity Markers

Hospitalization and ICU Requirements:

  • 18.9% of hospitalized adults with RSV require intensive care 5
  • Among adults ≥60 years, 19% experience serious clinical outcomes (hospitalization, ED visit, or pneumonia) 4
  • Patients living in residential facilities have 4.43-fold greater likelihood of severe RSV infection 4

Mortality:

  • In-hospital mortality: 4.6% (ages 60-74) and 6.1% (ages ≥75) 4
  • Advanced age >75 years associated with:
    • Poorer 30-day survival (aHR = 2.85)
    • Poorer 60-day survival (aHR = 2.10)
    • Longer hospitalization duration 4
  • RSV hospitalization and mortality rates are similar to influenza in older adults 4

Functional Decline:

  • Acute functional decline occurs in hospitalized adults ≥60 years 4
  • 6-month IADL scores decline by 66% for those admitted from skilled nursing facilities 4
  • Prolonged loss of function persists in some patients 4

Common colds typically resolve within 7-10 days without significant functional impairment or mortality risk.

Treatment Differences

RSV Management

Current Treatment Limitations:

  • No specific antiviral treatment exists for RSV 2
  • Supportive care is the mainstay of management 5, 2
  • Severe cases may require:
    • Oxygen therapy
    • High-flow nasal cannula 2
    • Mechanical ventilation 5
    • ICU admission

Prevention Strategies (Major Advancement):

Vaccines for Adults ≥60 Years:

  • Three FDA-approved vaccines as of 2024 6, 7:
    • Arexvy (GSK)
    • Abrysvo (Pfizer)
    • mResvia (Moderna)

Updated 2024 ACIP Recommendations 6:

  • All adults ≥75 years should receive single dose RSV vaccine
  • Adults 60-74 years at increased risk for severe RSV should receive vaccine
  • Adults who previously received RSV vaccine should not receive another dose

High-Risk Conditions for Ages 60-74 4, 6:

  • Chronic cardiovascular disease
  • Chronic lung/respiratory disease (especially COPD, asthma)
  • End-stage renal disease
  • Diabetes
  • Neurologic/neuromuscular conditions
  • Chronic liver disease
  • Chronic hematologic conditions
  • Severe obesity
  • Moderate/severe immunocompromise
  • Nursing home residence

Infant Prevention:

  • Monoclonal antibodies (Nirsevimab, Clesrovimab) for infants and high-risk children up to 24 months 7, 8
  • Maternal vaccination during pregnancy (Abrysvo) 7

Common Cold Management

Treatment:

  • Symptomatic relief only
  • No vaccines available
  • No specific antivirals needed
  • Self-limited course

Clinical Pitfalls to Avoid

  1. Do not dismiss RSV as "just another cold" in high-risk patients - it carries influenza-level morbidity and mortality 4

  2. Recognize that clinical features alone cannot differentiate RSV from other viral infections 5 - PCR testing is the gold standard for diagnosis

  3. Be aware that comorbidities increase with age in RSV patients - 25% in <6 months, 46% in 6-24 months, 70% in >24-59 months 3

  4. RSV-viral codetections increase severity risk in younger patients (<6 and 6-24 months) 3

  5. Frailty assessment matters - pre-hospitalization living situation predicts long-term morbidity and mortality 4

  6. The 2024 recommendation change from shared clinical decision-making to age-based recommendation aims to maximize vaccination coverage among those most likely to benefit 6

References

1
Research

Respiratory Syncytial Virus.

Pediatric annals, 2022

2
Research

Respiratory Syncytial Virus Infection: An Update.

Indian journal of pediatrics, 2023

3
Research

Age-specific predictors of disease severity in children with respiratory syncytial virus infection beyond infancy and through the first 5 years of age.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2024

Related Questions

For a child diagnosed with respiratory syncytial virus (RSV), how many days should they stay out of school before returning?
What is the recommended inpatient management for respiratory syncytial virus (RSV) infection?
What is the appropriate treatment for a 30-year-old patient with a one-week history of respiratory syncytial virus infection?
What is the typical recovery time for a healthy child with a mild Respiratory Syncytial Virus (RSV) infection?
What is the appropriate treatment for respiratory syncytial virus (RSV) infection?
Do diuretics provide benefit in treating lymphedema?
What does mild to moderate tricompartmental osteoarthritis, most pronounced in the medial compartment, indicate on a knee radiograph?
What is the APOA1 genetic marker?
In a patient with a persistent cough and a negative initial chest X‑ray, should a low‑dose chest CT be performed instead of repeating the X‑ray?
Should a 38-year-old surgical postmenopausal woman starting a transdermal estrogen patch begin mammogram screening before age 40?
What does a low alanine aminotransferase (ALT/SGPT) level indicate and what are its possible causes?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.